Rocket Pharmaceuticals, Inc. RCKT
2.60
(0.09)
(3.35%)
as of 25 Sep
- Market cap
- $300.8M
- P/E
- 0.0×
Follow RCKT
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
7.30 | 6.38 | 6.12 | 9.24 |
Net Debt/EBITDA |
4.15 | 4.09 | 2.70 | 5.90 | |
Debt/Assets |
5.26% | 5.86% | 6.78% | 4.57% | |
Debt/Equity |
0.06 | 0.07 | 0.08 | 0.05 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 0.82 | 0.95 | (0.32) | |
Capex/Depreciation |
0.02 | (0.03) | (0.04) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.17 | 0.19 | 0.23 | 0.15 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.45) | (0.31) | (0.41) | (0.35) | |
Cash per Share |
2.00 | 1.70 | 1.29 | 2.51 | |
Shareholders Equity per Share |
2.81 | 2.49 | 2.12 | 3.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.81 | 2.49 | 2.12 | 3.27 | |
Free Cash Flow |
(50.37) | (34.92) | (45.49) | (39.62) | |
Working Capital |
196.51 | 162.53 | 125.36 | 258.23 | |
Capital Expenditures |
0.05 | (0.08) | (0.09) | (0.01) | |
Net Current Asset Value |
173.32 | 139.51 | 102.46 | 235.28 | |
| Other line items | |||||
Quick Ratio |
7.15 | 6.25 | 5.90 | 9.06 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.31) | (0.40) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
32.70 | 32.56 | 26.99 | 34.42 | |
Average Assets |
380.86 | 429.07 | 378.24 | 422.04 | |
Average Common Equity |
321.72 | 370.23 | 325.09 | 361.52 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates